Research graph

References

References from Charting the future of biomarkers and therapy in Alzheimer's disease. Local targets link to admitted publications; unresolved targets remain external evidence.

Lecanemab in early Alzheimer's disease

10.1056/nejmoa2212948 · 2023 · External reference

Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial

10.1001/jama.2023.13239 · 2023 · External reference

New landscape of the diagnosis of Alzheimer's disease

10.1016/s0140-6736(25)01294-2 · 2025 · External reference

Fluid biomarkers in the evolving care landscape of Alzheimer's disease and related disorders

10.1016/s1474-4422(26)00246-2 · 2026 · Admitted local publication

Neuroimaging in the era of biologically defined Alzheimer's disease and disease-modifying therapy

10.1016/s1474-4422(26)00285-1 · 2026 · Admitted local publication

Clinical pathways for cognitively unimpaired individuals with Alzheimer's disease neuropathological change

10.1016/s1474-4422(26)00248-6 · 2026 · Admitted local publication

Comprehensive evaluation of plasma tau biomarkers for detecting and monitoring Alzheimer's disease in a multicenter and multiethnic aging population

10.1038/s43587-025-00904-3 · 2025 · External reference

Prognostic value of blood-based p-tau217 levels for progression to cognitive impairment

10.1001/jama.2026.12556 · 2026 · External reference

Amyloid PET quantitation and centiloid thresholds in the diagnosis of Alzheimer disease: an individual participant data meta-analysis

10.1001/jama.2026.13116 · 2026 · External reference